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Articles
First estimates of the global and regional incidence of 
neonatal herpes infection
Katharine J Looker, Amalia S Magaret, Margaret T May, Katherine M E Turner, Peter Vickerman, Lori M Newman, Sami L Gottlieb
Summary
Background Neonatal herpes is a rare but potentially devastating condition with an estimated 60% fatality rate without 
treatment. Transmission usually occurs during delivery from mothers with herpes simplex virus type 1 (HSV-1) or 
type 2 (HSV-2) genital infection. However, the global burden has never been quantiﬁ ed to our knowledge. We 
developed a novel methodology for burden estimation and present ﬁ rst WHO global and regional estimates of the 
annual number of neonatal herpes cases during 2010–15.
Methods We applied previous estimates of HSV-1 and HSV-2 prevalence and incidence in women aged 15–49 years to 
2010–15 birth rates to estimate infections during pregnancy. We then applied published risks of neonatal HSV 
transmission according to whether maternal infection was incident or prevalent with HSV-1 or HSV-2 to generate 
annual numbers of incident neonatal infections. We estimated the number of incident neonatal infections by 
maternal age, and we generated separate estimates for each WHO region, which were then summed to obtain global 
estimates of the number of neonatal herpes infections. 
Findings Globally the overall rate of neonatal herpes was estimated to be about ten cases per 100 000 livebirths, 
equivalent to a best-estimate of 14 000 cases annually roughly (4000 for HSV-1; 10 000 for HSV-2). We estimated that 
the most neonatal herpes cases occurred in Africa, due to high maternal HSV-2 infection and high birth rates. HSV-1 
contributed more cases than HSV-2 in the Americas, Europe, and Western Paciﬁ c. High rates of genital HSV-1 
infection and moderate HSV-2 prevalence meant the Americas had the highest overall rate. However, our estimates 
are highly sensitive to the core assumptions, and considerable uncertainty exists for many settings given sparse 
underlying data.
Interpretation These neonatal herpes estimates mark the ﬁ rst attempt to quantify the global burden of this rare but 
serious condition. Better collection of primary data for neonatal herpes is crucially needed to reduce uncertainty and 
reﬁ ne future estimates. These data are particularly important in resource-poor settings where we may have 
underestimated cases. Nevertheless, these ﬁ rst estimates suggest development of new HSV prevention measures 
such as vaccines could have additional beneﬁ ts beyond reducing genital ulcer disease and HSV-associated HIV 
transmission, through prevention of neonatal herpes.
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Introduction
Neonatal infection with herpes simplex virus (HSV) is a 
potentially devastating complication of genital herpes 
during pregnancy. It is rare but is associated with 
considerable morbidity and mortality: untreated, the 
case-fatality rate is estimated to be 60%.1,2 Even with 
antiviral treatment, mortality rates and lasting 
neurological impairment remain substantial, especially 
for neonates with CNS disease (about 30% of cases) and 
disseminated disease (25% of cases) compared with 
those with skin, eyes, and mucosa disease (around 45% 
of cases).1,2 Neonatal herpes infection is a costly condition 
since it typically involves a hospital stay, intensive 
monitoring, intravenous drug treatment, and extensive 
laboratory testing, and often results in long-term costs 
associated with disability due to severe neurological 
sequelae.3–5
The majority (>85%) of neonatal herpes infections occur 
from exposure to HSV type 1 (HSV-1) or type 2 (HSV-2) 
shed in the genital tract during delivery.1,6 Neonatal herpes 
infection due to a prevalent maternal infection is possible 
but the risk is low because of the presence of protective 
maternal IgG antibodies, which are able to cross the 
placenta to aﬀ ord immunity to the neonate.1,7 The risk of 
neonatal herpes infection is considerably greater for 
incident maternal infections close to term, when virus is 
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shed from the genital tract, but maternal IgG antibodies 
have yet to be produced.1,7 Intrauterine infection, although 
highly morbid, accounts for less than 5% of neonatal 
herpes infections.1,6 Post-partum infection (around 10% of 
cases) is thought to be acquired through contact with oral 
HSV-1 shed by caregivers.1,6
Worldwide, HSV-1 and HSV-2 are both highly 
prevalent.8–12 HSV-2 is predominantly sexually transmitted 
and it causes genital herpes. HSV-1 is predominantly orally 
transmitted and it causes orolabial herpes (ie, cold sores); 
however, genital HSV-1 infection is possible. In 2012, an 
estimated 417 million people aged 15–49 years had 
prevalent HSV-2 infection globally.8 Since serological tests 
do not distinguish between orolabial and genital infection, 
it is diﬃ  cult to accurately estimate the global number of 
prevalent genital HSV-1 infections. Estimates for 2012 
put the ﬁ gure among people aged 15–49 years at 
140–239 million, depending on the value taken for the 
proportion of incident HSV-1 infections that are genital 
after age 15 years.9 Evidence suggests that the prevalence of 
genital HSV-1 is increasing in some high-income settings, 
and that it is becoming an important cause of genital 
herpes,13 which may increase rates of neonatal herpes.
The occurrence of neonatal herpes has been diﬃ  cult 
to quantify, and the worldwide annual number of cases 
has never been estimated. Most countries do not 
require case-reporting of neonatal herpes infections,4 
although a few areas have implemented active 
surveillance eﬀ orts for this disorder.14,15 Prospective 
cohort studies that measure incidence have been done 
only rarely.7 Without estimates of the numbers of cases 
of neonatal herpes occurring each year, it is challenging 
to raise awareness of this devastating infection. 
Additionally, global estimates are crucial for stimulating 
eﬀ orts to develop HSV vaccines, microbicides, and 
improved diagnostics and treatment, and for modelling 
more precisely their potential beneﬁ ts. Therefore, we 
present the ﬁ rst set of WHO global estimates of the 
annual number of incident cases of neonatal herpes 
infection from HSV-1 or HSV-2 infection in mothers 
aged 15–49 years during 2010–15.
Methods
To generate estimates of incident neonatal herpes cases 
worldwide, we used as our starting point the latest 
WHO global and regional estimates of HSV-1 and 
HSV-2 prevalence and incidence in women, which were 
done for 2012 and published in 2015.8,9 These estimates 
were informed by comprehensive literature reviews 
conducted up to February, 2014; full details of the search 
strategy, methods, and results are reported in the 
corresponding papers.8,9 After applying livebirth rates by 
maternal age group for each WHO region for 2010–1516 
to determine estimates of the prevalence and incidence 
of maternal HSV infections during pregnancy, we 
applied published risks of neonatal transmission 
according to whether the maternal infection was 
incident or prevalent and type 1 or type 2,7,17,18 to generate 
annual numbers of incident neonatal infections 
according to the equation in ﬁ gure 1.
Table 1 displays the key parameter values used in the 
estimates. Estimates of numbers of incident neonatal 
Research in context
Evidence before this study
Neonatal herpes is rare but often leads to death or lifelong 
disability. Although some surveillance and other studies have 
assessed neonatal herpes incidence in selected high-income 
country settings, the global burden has never been estimated to 
our knowledge. Additionally, no estimates of neonatal herpes 
incidence seem to exist for resource-poor settings. Particularly in 
areas with high prevalence of genital infection with herpes 
simplex virus (HSV) in adults and poor medical infrastructure for 
prevention, diagnosis, and management, neonatal herpes could 
be an important under-recognised cause of neonatal morbidity 
and mortality. Following completion of the ﬁ rst global estimates 
of HSV-1 infection and updated global estimates of HSV-2 
infection in 2015, we estimated the global burden of neonatal 
herpes incorporating the underlying epidemiology of HSV 
infections in the population.
Added value of this study
This study presents the ﬁ rst WHO global and regional estimates 
of the annual number of incident neonatal herpes infections 
during 2010–15. Our estimation process uses estimates of 
HSV infection in women by age and WHO region and published 
mother-to-child transmission risks according to maternal 
infection characteristics. This process enabled us to demonstrate 
important diﬀ erences in the distribution of cases by geographic 
region, for example, the proportion of cases caused by HSV-1 
and the role of incident maternal infection. However, this study 
also highlights the lack of epidemiological data to inform and 
validate the estimates in some settings. In particular, because 
we extrapolate estimates using transmission risk data from the 
USA, we have probably underestimated neonatal herpes cases in 
some low-resource settings.
Implications of all the available evidence
Primary data on neonatal herpes incidence in resource-poor 
settings are crucial to more accurately quantify the mortality 
and morbidity attributable to neonatal herpes and guide future 
prevention eﬀ orts. Generating ﬁ rst estimates of the global 
burden of neonatal herpes is a crucial ﬁ rst step in raising 
awareness of this condition and guiding investment in future 
interventions such as vaccines and microbicides, by informing 
the full range and distribution of disease attributable to HSV 
infection, and therefore, the maximum potential beneﬁ t of 
these interventions. 
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infections were done for each single year of maternal age 
(15–49 years) and then summed across each 5-year 
maternal age group. Separate estimates were produced 
for each WHO region (the Americas, Africa, Eastern 
Mediterranean, Europe, Southeast Asia, and Western 
Paciﬁ c) and then summed to obtain global estimates of 
the number of neonatal herpes infections. A sensitivity 
analysis was carried out varying the assumed risks of 
neonatal transmission (table 1). For full details of the 
methods see appendix.
Role of the funding source
This work was funded by the UNDP/UNFPA/UNICEF/
WHO/World Bank Special Programme of Research, 
Development and Research Training in Human 
Reproduction. WHO commissioned the study, advised as 
required, coordinated data requests, helped with redrafts, 
and approved manuscript submission. KJL had full 
access to all data in the study and had ﬁ nal responsibility 
for the decision to submit for publication.
Results
Findings of the previous HSV estimates that are relevant 
to the current estimates of neonatal herpes cases are 
presented in the appendix.8,9 Globally, of the 139 million 
livebirths among women aged 15–49 years each year 
during 2010–15 on average, an estimated 24 million 
births occurred to women who had either prevalent or 
incident HSV-2 infection during pregnancy, and 
108 million births occurred to women who had either 
prevalent or incident HSV-1 infection (at any site) during 
pregnancy (some of which—ie, those births in dually 
infected mothers—were counted among the numbers 
with HSV-2 infection).
Globally, the annual number of incident neonatal 
herpes cases during 2010–15 was estimated to be 14 257, 
of which approximately two-thirds (9911 cases) were due 
to HSV-2, and a third (4346 cases) were due to HSV-1 
(table 2). The global rate of neonatal herpes when 
averaged across all regions was estimated to be 10·3 per 
100 000 livebirths (table 3).
Symbol Default value Range used in 
sensitivity analysis
Reference(s)
HSV-2
Average number of days between HSV-2 infection and the 
development of protective IgG antibodies (=transmission window)
xHSV-2 21 days NA Ashley et al,19 Ashley-Morrow et al20
Risk of neonatal infection from a prevalent maternal HSV-2 infection rprev_HSV-2 0·02% 0·0045% and 0·064% Brown et al7
Risk of neonatal infection from an incident maternal HSV-2 infection 
that occurs near labour and before antibodies have developed
rincid_HSV-2 7·7% 2·7% and 15·4% Brown et al,7 Phipps et al17
HSV-1
Average number of days between HSV-1 infection and the 
development of protective IgG antibodies (=transmission window)
xHSV-1 25 days NA Ashley-Morrow et al 20
Risk of neonatal infection from a prevalent maternal HSV-1 
infection (any HSV-1 infection)
rprev_HSV-1 0·0063% 0·00077% and 0·023% Brown et al7 and Stacy Selke, 
personal communication
Risk of neonatal infection from an incident maternal HSV-1 
infection (any HSV-1 infection) that occurs near labour and before 
antibodies have developed
rincid_HSV-1 11% 3·1% and 26·1% Brown et al7 and Amalia Magaret, 
personal communication, based on 
data described in Delaney et al18
For full details see appendix. HSV=herpes simplex virus. NA=not applicable.
Table 1: Key parameter values used in the estimates and accompanying range used in the sensitivity analysis 
See Online for appendix
×= × + × ×
Fraction of
mothers with 
prevalent 
HSV-s infection
Number of
livebirths
Risk of neonatal 
herpes from a 
prevalent 
maternal HSV-s 
infection
Fraction of mothers 
susceptible to HSV-s 
infection
Risk of an incident 
maternal HSV-s infection 
occurring near labour in 
which antibodies have yet 
to develop
Risk of neonatal 
herpes from an 
incident maternal 
HSV-s infection
that occurs near 
labour and before 
antibodies have 
developed
Number of 
neonatal 
infections due
to HSV-s
N(a)HSV-s B(a) [(F(a)HSV-s rprev_HSV-s) ((kHSV-s – F(a)HSV-s) λHSV-s  ×  (xHSV-s/365) rincid_HSV-s))]
Figure 1: Equation used to generate annual numbers of incident neonatal infections
For this equation, N(a)HSV-s is the annual number of incident neonatal HSV infections corresponding to maternal year of age a due to HSV type s where s=1 or 2; B(a) is 
the annual number of livebirths at maternal age a;16 F(a)HSV-s is the proportion of women with prevalent HSV-s infection at age a;8,9 rprev_HSV-s is the per-birth risk of 
neonatal infection from a prevalent maternal HSV-s infection;7 kHSV-s is the maximum proportion of women that can be expected to be infected with HSV-s over a 
lifetime of exposure;8,9 λHSV-s is the incidence of HSV-s infection per year among (uninfected) women;8,9 xHSV-s is the average number of days between HSV-s infection and 
the development of protective IgG antibodies (ie, the window for transmission associated with an incident maternal HSV-s infection);19,20 rincid_HSV-s is the per-birth risk of 
neonatal infection from an incident maternal HSV-s infection that occurs near labour and before antibodies have developed.7,17,18
Articles
e303 www.thelancet.com/lancetgh   Vol 5   March 2017
Our results showed that Africa contributed the largest 
proportion (around a third) of neonatal herpes cases to the 
global total (table 2; ﬁ gure 2). This result was a 
consequence of a very high incidence and prevalence of 
adult female HSV-2 infection in this region (appendix), 
combined with high number of births (appendix). Our 
calculations showed that HSV-1 was not an important 
cause of neonatal herpes in Africa (table 2; ﬁ gure 2). This 
ﬁ nding was based on available data showing a high 
modelled rate of (oral) HSV-1 infection during childhood 
and saturation in prevalence by adolescence at almost 
100% prevalence in Africa, thus removing potential for 
further genital HSV-1 infection in adulthood (appendix). 
HSV-1 did not seem to be a substantial cause of neonatal 
herpes in Southeast Asia either (table 2; ﬁ gure 2), again 
based on available data, which seemed to show saturation 
in HSV-1 prevalence by adolescence, although the 
modelled level of saturation in Southeast Asia was much 
lower than that in Africa (appendix).
By contrast, HSV-1 was estimated to cause more 
neonatal herpes cases than HSV-2 in the Americas, and 
also in Europe and Western Paciﬁ c (table 2; ﬁ gure 2). 
The high numbers of neonatal herpes cases due to 
HSV-1 in the Americas were due to relatively low rates 
of childhood HSV-1 infection, with new HSV-1 
infections continuing to occur during adulthood 
(appendix), and the attendant risk to the neonate from 
genital HSV-1. High rates of genital HSV-1 relative to 
other regions, combined with moderately high HSV-2 
prevalence among women, meant that the Americas 
was estimated to have the highest overall rate of 
neonatal herpes in the world: 19·9 per 100 000 livebirths 
(all births, not just those of infected women; table 3).
The number of neonatal herpes cases by maternal age 
group increased between the age groups 15–19 and 
20–24 years (from 1884 to 4530 cases) and decreased 
thereafter (table 2). This increase was largely due to the 
steep rise in number of births by maternal age group. 
Neonatal herpes incidence decreased with increased 
maternal age for HSV-1, whereas HSV-2 incidence 
decreased with increased age from the age groups 
15–19 years to 25–29 years but then increased again from 
30–34 years until 45–49 years (table 3). These patterns 
were reﬂ ected in an overall trend of increasing proportion 
of cases due to HSV-2 with maternal age (ﬁ gure 3).
Patterns in rates are a product of the proportion of 
women with incident versus prevalent infection, and the 
risks of transmission associated with each. Neonatal 
Maternal age group (years) Total
15–19 20–24 25–29 30–34 35–39 40–44 45–49
Any neonatal herpes
Americas 484 (3%) 864 (6%) 818 (6%) 565 (4%) 278 (2%) 72 (1%) 10 (<1%) 3091 (22%)
Africa 934 (7%) 1521 (11%) 1282 (9%) 847 (6%) 460 (3%) 168 (1%) 59 (<1%) 5270 (37%)
Eastern Mediterranean 152 (1%) 307 (2%) 269 (2%) 161 (1%) 78 (1%) 26 (<1%) 6 (<1%) 1000 (7%)
Europe 79 (1%) 256 (2%) 312 (2%) 232 (2%) 99 (1%) 20 (<1%) 1 (<1%) 999 (7%)
Southeast Asia 103 (1%) 459 (3%) 402 (3%) 212 (1%) 96 (1%) 30 (<1%) 10 (<1%) 1313 (9%)
Western Paciﬁ c 131 (1%) 1123 (8%) 848 (6%) 319 (2%) 119 (1%) 37 (<1%) 6 (<1%) 2583 (18%)
Global total 1884 (13%) 4530 (32%) 3930 (28%) 2336 (16%) 1131 (8%) 353 (2%) 92 (1%) 14 257 (100%)
Neonatal herpes due to a maternal HSV-1 infection
Americas 358 (8%) 587 (14%) 507 (12%) 320 (7%) 143 (3%) 34 (1%) 4 (<1%) 1954 (45%)
Africa 11 (<1%) 4 (<1%) 2 (<1%) 1 (<1%) 1 (<1%) 0 0 19 (<1%)
Eastern Mediterranean 74 (2%) 113 (3%) 76 (2%) 38 (1%) 17 (<1%) 5 (<1%) 1 (<1%) 325 (7%)
Europe 62 (1%) 174 (4%) 179 (4%) 113 (3%) 42 (1%) 8 (<1%) 0 577 (13%)
Southeast Asia 18 (<1%) 20 (<1%) 8 (<1%) 3 (<1%) 1 (<1%) 0 0 51 (1%)
Western Paciﬁ c 99 (2%) 706 (16%) 430 (10%) 131 (3%) 41 (1%) 11 (<1%) 2 (<1%) 1420 (33%)
Global total 622 (14%) 1604 (37%) 1202 (28%) 606 (14%) 246 (6%) 59 (1%) 8 (<1%) 4346 (100%)
Neonatal herpes due to a maternal HSV-2 infection
Americas 126 (1%) 277 (3%) 310 (3%) 245 (2%) 134 (1%) 38 (<1%) 6 (<1%) 1137 (11%)
Africa 924 (9%) 1517 (15%) 1280 (13%) 846 (9%) 460 (5%) 167 (2%) 59 (1%) 5252 (53%)
Eastern Mediterranean 78 (1%) 194 (2%) 193 (2%) 123 (1%) 61 (1%) 21 (<1%) 5 (<1%) 675 (7%)
Europe 17 (<1%) 82 (1%) 133 (1%) 119 (1%) 57 (1%) 12 (<1%) 1 (<1%) 422 (4%)
Southeast Asia 86 (1%) 439 (4%) 394 (4%) 209 (2%) 95 (1%) 30 (<1%) 10 (<1%) 1262 (13%)
Western Paciﬁ c 32 (<1%) 417 (4%) 418 (4%) 188 (2%) 78 (1%) 26 (<1%) 4 (<1%) 1163 (12%)
Global total 1262 (13%) 2927 (30%) 2729 (28%) 1730 (17%) 885 (9%) 294 (3%) 84 (1%) 9911 (100%)
Totals might vary due to rounding. Numbers of cases are given to the nearest integer. It should be noted that all numbers are model estimates. Measurement resolution 
should not be interpreted as indicative of precision. HSV=herpes simplex virus.
Table 2: Global and regional estimates of the annual number of cases of neonatal herpes during 2010–15, by HSV type and maternal age group 
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herpes incidence rates due to HSV-1 declined with 
increased maternal age because the number of women 
able to be newly infected with HSV-1 decreased with age, 
and the risk associated with prevalent maternal HSV-1 
infection is low relative to that for incident maternal 
infection. For HSV-2, global trends masked quite diﬀ erent 
regional trends. The incidence of neonatal herpes 
infection increased with maternal age in regions where 
new maternal HSV-2 infections continued to occur at 
older ages and prevalence increased with age (Americas, 
Europe, Southeast Asia, and Western Paciﬁ c) but 
decreased in regions where new infections slowed and 
maternal HSV-2 prevalence reached saturation at older 
maternal ages (Africa and Eastern Mediterranean; 
table 3).
We calculated that the proportion of cases of neonatal 
herpes was split roughly equally between prevalent versus 
incident maternal HSV infections, although some regional 
diﬀ erences were seen, with most cases attributable to 
incident maternal infection in Europe, Southeast Asia, 
Western Paciﬁ c, and, most markedly, the Americas 
(ﬁ gure 2). However, the relative contribution of prevalent 
versus incident HSV infection to neonatal herpes cases 
showed a strong association with maternal age (ﬁ gure 3).
The number and rate of neonatal herpes is sensitive to 
the assumed risks of neonatal herpes from a maternal 
infection (HSV-1 vs HSV-2; incident vs prevalent 
infection), reﬂ ecting the underlying uncertainty in the 
values attached to these risks (tables 4 and 5). The 
variation in numbers of cases and rates between the 
lowest and highest assumed values was an order of 
magnitude of approximately 10. When we used the 
lowest values across all assumptions, the total annual 
number of cases of neonatal herpes globally during 
2010–15 was estimated to be 3703 (2·7 cases per 
100 000 livebirths), and when the highest values were 
used across all assumptions, the total annual number of 
cases worldwide in 2010–15 was estimated to be 
36 415 (26·3 cases per 100 000 livebirths).
Discussion
This is the ﬁ rst attempt to quantify the global number of 
incident neonatal herpes cases. We estimated that every 
year during 2010–15 over 14 000 cases of neonatal herpes 
arose from HSV infection in mothers aged 15–49 years 
worldwide (HSV-1: about 4000; HSV-2: about 10 000), 
which is equivalent to an annual rate of neonatal herpes 
of 10·3 per 100 000 livebirths. Our estimates of neonatal 
herpes cases are highly sensitive to the assumptions 
made. For example, the numbers of annual cases could 
be roughly as low as 4000 or as high as 36 000, if the 
lowest or highest plausible values for all components of 
neonatal transmission risk are used. Nonetheless, these 
estimates enable us to gain a ﬁ rst insight into the global 
picture of neonatal herpes, to compare burden of cases 
between regions, including the impact of HSV-1 versus 
HSV-2 and prevalent versus incident maternal infection, 
and to understand where further data collection is 
needed. For example, the Americas had the highest 
estimated regional rate of neonatal herpes, in large part 
because of the role of HSV-1 infection, which contributed 
two-thirds of cases to the regional total. This ﬁ nding is 
consistent with recent surveillance data from Canada 
showing that HSV-1 caused 63% of neonatal herpes 
cases.15 By contrast, in Africa, almost all cases were due to 
HSV-2, and high HSV-2 infection rates combined with 
high birth rates in this region led it to have the highest 
estimated number of cases globally.
Our global estimated neonatal herpes rate of 10·3 per 
100 000 livebirths is consistent with recent estimates 
from North America, Europe, and Australia using 
surveillance and administrative data, which have ranged 
between 2·5 and 13·3 per 100 000 livebirths.1,5,14,15,21–26 The 
global number of cases we estimated is similar to what 
would be expected if neonatal herpes rates from the 
largest recent population-based estimates from US 
hospital discharge data (9·6 per 100 000 livebirths) were 
Maternal age group (years) Overall 
rate per 
100 000 
livebirths
15–19 20–24 25–29 30–34 35–39 40–44 45–49
Any neonatal herpes
Americas 22·1 20·6 19·5 18·8 18·4 18·1 18·1 19·9
Africa 18·4 16·2 14·9 14·0 13·5 13·1 12·8 15·4
Eastern Mediterranean 12·4 7·9 5·9 5·0 4·7 4·5 4·4 6·5
Europe 14·9 10·9 8·7 7·6 7·1 6·9 6·8 8·9
Southeast Asia 3·2 3·3 3·6 4·1 4·5 4·9 5·3 3·6
Western Paciﬁ c 15·3 1··3 9·3 8·4 8·1 8·0 8·1 10·0
Global total 14·4 10·3 9·6 9·6 9·7 9·7 9·8 10·3
Neonatal herpes due to a maternal HSV-1 infection
Americas 16·3 14·0 12·1 10·6 9·5 8·6 7·9 12·6
Africa 0·2 0·04 0·02 0·02 0·02 0·02 0·02 0·05
Eastern Mediterranean 6·1 2·9 1·7 1·2 1·0 0·9 0·9 2·1
Europe 11·7 7·4 5·0 3·7 3·0 2·6 2·4 5·2
Southeast Asia 0·5 0·1 0·07 0·06 0·06 0·06 0·06 0·1
Western Paciﬁ c 11·6 7·1 4·7 3·5 2·8 2·5 2·3 5·5
Global total 4·7 3·7 2·9 2·5 2·1 1·6 0·9 3·1
Neonatal herpes due to a maternal HSV-2 infection
Americas 5·7 6·6 7·4 8·2 8·9 9·6 10·2 7·3
Africa 18·2 16·2 14·9 14·0 13·4 13·1 12·8 15·3
Eastern Mediterranean 6·4 5·0 4·2 3·9 3·6 3·5 3·5 4·4
Europe 3·2 3·5 3·7 3·9 4·1 4·3 4·4 3·8
Southeast Asia 2·7 3·1 3·6 4·0 4·4 4·9 5·3 3·5
Western Paciﬁ c 3·7 4·2 4·6 4·9 5·3 5·6 5·9 4·5
Global total 9·6 6·7 6·6 7·1 7·6 8·1 9·0 7·2
Rates are given to 1 decimal place or 2 decimal places for very low rates, to demonstrate trends. It should be noted that 
all rates are model estimates. Measurement resolution should not be interpreted as indicative of precision. 
HSV=herpes simplex virus. 
Table 3: Global and regional estimates of the annual incidence of neonatal herpes per 100 000 livebirths 
during 2010–15, by HSV type and maternal age group 
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applied to global births.5 Our higher estimated rate of 
19·9 cases per 100 000 livebirths for the Americas might 
reﬂ ect the challenges of retrospective reviews and 
diﬃ  culty capturing all cases for a condition that has not 
always had a single clear diagnosis code, and the overall 
uncertainty inherent in our estimates. A rate of 30·8 per 
100 000 livebirths was found in the only large multicentre 
prospective study of neonatal herpes acquisition, which 
was the study that informed our underlying neonatal 
transmission risks.7 Globally, comparisons with other 
region-speciﬁ c rates are made diﬃ  cult by a general lack 
of data with regard to neonatal herpes.27
These global neonatal herpes estimates provide a 
starting point for understanding the burden of neonatal 
herpes worldwide; however, it is likely that we have 
underestimated the numbers of cases in resource-poor 
settings. Our estimates rely heavily on data from the 
USA for parameterising transmission risks. We used 
numbers from a large, multicentre prospective study in 
the USA of the eﬀ ect of maternal HSV shedding and 
serological status on risk of transmission to the neonate,7 
but this study might not be generalisable to other 
settings. For example, the overall neonatal transmission 
risks in this study incorporated routine use of caesarean 
section when genital lesions were present as well as for 
other indications, which was shown to substantially 
reduce the risk of neonatal herpes infection.7 Thus, the 
risks and corresponding number of cases could be much 
higher in settings where caesarean section is not 
frequently performed. Findings from studies have also 
shown that HIV infection increases genital HSV-2 
shedding frequency and quantity.28,29 A recent study in 
South Africa of women in labour found high frequency 
of HSV-2 shedding at delivery, especially in women co-
infected with HIV.27 Neonatal herpes rates could therefore 
be even higher in regions with substantial HIV burden 
in women of reproductive age.27
*Rates per 100 000 live births
19·9*
15·4*
10·0*
6·5* 3·6*
8·9*
Americas Africa
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Figure 3: Percentage of neonatal herpes cases due to (A) HSV-1 versus HSV-2; and (B) prevalent versus 
incident maternal HSV infection during 2010–15, by age group of the mother
Figure 2: Estimates of the annual number of cases and rate per 100 000 livebirths of neonatal herpes during 2010–15 (B), and relative contribution of HSV-1 versus HSV-2 (A) and prevalent 
versus incident HSV infection in the mother (C) to the numbers of cases, by WHO region
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Additionally, these estimates are an attempt to quantify 
only the number of cases of neonatal herpes, and do not 
tell us anything about the severity of infection. The clinical 
course of neonatal herpes, and the case-fatality rate, 
depend much on whether or not antivirals are given and 
how promptly, and thus will vary substantially by setting. 
In areas with less developed medical infrastructure and 
limited diagnostic testing, neonatal herpes might be 
missed or mistaken for other serious illnesses, resulting 
in a higher burden of death and neurological sequelae.2 If 
we use a value of 60% for the proportion of neonatal cases 
that are fatal if left untreated,1,2 then a rough estimate of 
the upper limit of the mortality rate due to neonatal herpes 
is 0·062 per 1000 livebirths, or 8554 neonatal deaths 
annually given our base case scenario. This number does 
not of course consider those infants left with lifelong 
disability, which is also likely to reach the thousands.
Collecting primary data on the incidence of neonatal 
herpes in resource-poor settings, and especially in sub-
Saharan Africa, is therefore crucial. Preliminary data 
from a validation study of minimally invasive autopsy for 
evaluating neonatal deaths in Mozambique showed that 
HSV was the ﬁ nal cause of death in two of 41 neonatal 
deaths, and was a signiﬁ cant contributing factor in one 
of 18 stillbirths evaluated (Clara Menendez, personal 
communication). Although these are small numbers, 
these data indicate that neonatal herpes could be much 
under-appreciated as a cause of neonatal mortality in 
resource-poor settings. Expanded evaluations of neonatal 
deaths in these settings through the Child Health and 
Mortality Prevention Surveillance (CHAMPS) network 
will include HSV testing and will provide critical new 
data to understand the global impact of neonatal herpes.30
Our estimates have several other important limitations 
relevant to all regions. First, since these estimates of 
neonatal herpes cases are in turn based on the most 
recent estimates of prevalence and incidence of HSV-1 
and HSV-2 in women aged 15–49 years, the neonatal 
herpes estimates are aﬀ ected by the same data availability, 
generalisability, and quality issues as those aﬀ ecting the 
adult estimates.8,9 Individual studies can have a 
substantial inﬂ uence on the estimated burden of 
maternal infection by region, and, in turn, on the 
estimates of neonatal herpes cases. Our estimates of 
genital HSV-1 are particularly uncertain. We assumed a 
value for the proportion of incident adult HSV-1 
Maternal age group (years) Total
15–19 20–24 25–29 30–34 35–39 40–44 45–49
Any neonatal herpes
Americas 130–1193 223–2195 204–2135 136–1512 65–759 16–200 2–28 777–8022
Africa 291–2066 433–3645 336–3264 208–2252 107–1263 38–469 13–167 1425–13126
Eastern Mediterranean 43–360 80–784 63–736 35–465 16–233 5–78 1–19 243–2674
Europe 21–195 65–657 75–836 53–646 22–285 4–58 0–4 241–2680
Southeast Asia 32–231 135–1070 113–971 58–526 25–243 8–78 3–26 374–3146
Western Paciﬁ c 38–321 326–2863 243–2250 89–874 33–334 10–107 2–17 741–6767
Global total 552–4365 1225–11213 1000–10193 564–6275 262–3117 79–991 20–262 3703–36415
Neonatal herpes due to a maternal HSV-1 infection
Americas 90–918 141–1554 116–1388 70–904 30–418 7–102 1–14 454–5928
Africa 3–26 1–11 0–7 0–4 0–3 0–1 0–0 4–53
Eastern Mediterranean 19–187 26–308 15–229 6–125 2–59 1–19 0–5 69–932
Europe 16–157 41–466 38–512 21–346 7–136 1–25 0–2 124–1644
Southeast Asia 5–44 4–58 1–27 0–11 0–5 0–1 0–0 11–146
Western Paciﬁ c 25–251 166–1896 91–1238 24–405 7–135 2–39 0–6 315–3972
Global total 157–1584 379–4293 262–3401 122–1796 46–756 10–188 1–26 977–12045
Neonatal herpes due to a maternal HSV-2 infection
Americas 40–275 82–641 88–747 67–608 35–341 10–98 1–15 323–2724
Africa 289–2040 432–3633 336–3257 207–2248 107–1260 38–468 13–166 1421–13073
Eastern Mediterranean 24–173 54–476 48–508 29–339 14–174 4–59 1–14 173–1742
Europe 5–37 24–191 37–324 32–301 15–148 3–32 0–2 116–1036
Southeast Asia 27–187 131–1012 112–944 57–514 25–239 8–77 3–26 363–2999
Western Paciﬁ c 10–70 123–967 118–1012 51–468 20–199 7–68 1–11 329–2795
Global total 395–2781 846–6920 738–6792 442–4479 216–2361 69–802 19–235 2726–24370
Estimates are presented as lowest estimate–highest estimate. Totals might vary due to rounding. Numbers of cases are given in integers. It should be noted that all numbers 
are model estimates. Measurement resolution should not be interpreted as indicative of precision.
Table 4: Sensitivity analysis for estimates of annual neonatal herpes cases during 2010–15 by HSV type and maternal age group, varying neonatal herpes 
transmission risk 
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infections that are genital of 50%.31 To our knowledge, no 
published studies have estimated this proportion in 
settings outside the USA; however Africa, Eastern 
Mediterranean, and Southeast Asia seem to have little 
new HSV-1 infection in adults,9 so choice of parameter 
values for HSV-1 is less inﬂ uential in these regions.
Second, although the large, multicentre prospective 
study7 in the USA from which our transmission risks 
were taken followed up over 58 000 pregnant women, 
and represents the best available estimates of risk, the 
numbers of neonatal herpes cases in this study were 
extremely small: just 14 cases, which were used to inform 
our regional and global estimates. Our sensitivity 
analysis, which incorporated the conﬁ dence intervals 
around the risks from this source study, showed that 
varying the risks of neonatal transmission due to incident 
and prevalent maternal infection had a substantial eﬀ ect 
on the estimated numbers of neonatal herpes cases.
Finally, HSV incidence could be diﬀ erent between 
pregnant women and non-pregnant women; however, 
this is not well understood.32,33 Acquisition of genital 
herpes could be lower in pregnant women as a 
consequence of less frequent sexual activity, particularly 
during late-stage pregnancy, and lower partner change 
rates. However, changes in the maternal immune system 
could increase susceptibility to genital herpes during 
pregnancy,34 whereas lower rates of condom use might 
expose pregnant women to an increased risk of infection.
Genital HSV infections among adolescents and adults 
are a global public health problem, estimated to aﬀ ect 
over half a billion people worldwide.8,9 Our study is, to 
our knowledge, the ﬁ rst attempt to quantify and thus 
better understand the global burden of neonatal herpes. 
However, data on mother-to-child HSV transmission 
rates in less industrialised settings are absent, and we 
have instead relied on single studies of risk from the 
USA to generate estimates across all regions. In so doing, 
we might have underestimated neonatal herpes cases in 
resource-poor settings, perhaps severely. By highlighting 
the various limitations of these estimates, we hope to 
stimulate better and more coordinated data collection 
eﬀ orts to improve future estimates. Enhanced case 
reporting and surveillance where feasible and focused 
studies to collect prospective data on neonatal herpes 
Maternal age group (years) Overall rate 
per 100 000 
livebirths
15–19 20–24 25–29 30–34 35–39 40–44 45–49
Any neonatal herpes
Americas 5·9–54·4 5·3–52·2 4·9–50·9 4·5–50·3 4·3–50·2 4·1–50·5 4·0–51·1 5·0–51·6
Africa 5·7–40·7 4·6–38·9 3·9–37·9 3·4–37·3 3·1–36·9 2·9–36·7 2·8–36·5 4·2–38·3
Eastern Mediterranean 3·5–29·5 2·0–20·1 1·4–16·2 1·1–14·5 0·9–13·8 0·9–13·5 0·8–13·3 1·6–17·5
Europe 4·0–36·8 2·8–27·9 2·1–23·4 1·7–21·3 1·6–20·4 1·5–20·1 1·4–20·2 2·1–23·9
Southeast Asia 1·0–7·1 1·0–7·6 1·0–8·8 1·1–10·1 1·2–11·4 1·3–12·6 1·3–13·9 1·0–8·6
Western Paciﬁ c 4·5–37·6 3·3–28·7 2·7–24·7 2·4–23·1 2·2–22·7 2·2–23·0 2·1–23·5 2·9–26·3
Global total 4·2–33·3 2·8–25·5 2·4–24·8 2·3–25·8 2·3–26·8 2·2–27·3 2·2–27·9 2·7–26·3
Neonatal herpes due to a maternal HSV-1 infection
Americas 4·1–41·9 3·4–37·0 2·8–33·1 2·3–30·1 2·0–27·7 1·7–25·8 1·5–24·3 2·9–34·1
Africa 0·06–0·5 0·01–0·1 0·00–0·08 0·00–0·07 0·00–0·07 0·00–0·07 0·00–0·07 0·01–0·2
Eastern Mediterranean 1·6–15·3 0·7–7·9 0·3–5·0 0·2–3·9 0·1–3·5 0·1–3·3 0·1–3·3 0·5–6·1
Europe 3·0–29·8 1·7–19·8 1·1–14·3 0·7–11·4 0·5–9·8 0·4–8·9 0·3–8·4 1·1–14·7
Southeast Asia 0·1–1·4 0·03–0·4 0·01–0·2 0·01–0·2 0·01–0·2 0·01–0·2 0·01–0·2 0·03–0·4
Western Paciﬁ c 2·9–29·4 1·7–19·0 1·0–13·6 0·6–10·7 0·5–9·2 0·4–8·4 0·3–8·0 1·2–15·4
Global total 1·2–12·1 0·9–9·8 0·6–8·3 0·5–7·4 0·4–6·5 0·3–5·2 0·1–2·8 0·7–8·7
Neonatal herpes due to a maternal HSV-2 infection
Americas 1·8–12·5 2·0–15·2 2·1–17·8 2·2–20·2 2·3–22·5 2·5–24·7 2·6–26·8 2·2–17·5
Africa 5·7–40·2 4·6–38·8 3·9–37·9 3·4–37·2 3·1–36·8 2·9–36·6 2·8–36·4 4·1–38·2
Eastern Mediterranean 2·0–14·1 1·4–12·2 1·1–11·1 0·9–10·6 0·8–10·3 0·8–10·2 0·7–10·1 1·1–11·4
Europe 1·0–7·0 1·0–8·1 1·0–9·1 1·0–9·9 1·1–10·6 1·1–11·3 1·1–11·8 1·0–9·3
Southeast Asia 0·8–5·8 0·9–7·2 1·0–8·5 1·1–9·9 1·2–11·2 1·3–12·4 1·3–13·7 1·0–8·2
Western Paciﬁ c 1·2–8·2 1·2–9·7 1·3–11·1 1·3–12·4 1·4–13·5 1·4–14·6 1·4–15·5 1·3–10·9
Global total 3·0–21·2 1·9–15·8 1·8–16·5 1·8–18·4 1·9–20·3 1·9–22·1 2·0–25·1 2·0–17·6
Estimates are presented as lowest estimate–highest estimate. Rates are given to 1 decimal place, or 2 decimal places for very low rates, to demonstrate trends. It should be 
noted that all rates are model estimates. Measurement resolution should not be interpreted as indicative of precision.
Table 5: Sensitivity analysis for estimates of annual neonatal herpes incidence per 100 000 livebirths during 2010-15 by HSV type and maternal age 
group, varying neonatal herpes transmission risk
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incidence, mortality, and transmission risks will be very 
valuable. This need is particularly important for settings 
in sub-Saharan Africa, since low rates of caesarean 
section and generalised HIV epidemics have the potential 
to increase the number of neonatal herpes cases to a 
number well above that estimated here. Additional 
assessments of the incidence and prevalence of HSV-2 
and genital HSV-1 among women, especially in countries 
outside of North America and Europe, are also needed.
Neonatal herpes has high fatality rates and potential for 
long-term neurological disability in surviving neonates, 
but it is rare. This rarity leaves a quandary for appropriate 
targeting of prevention eﬀ orts, and at what cost, for the 
tens of millions of women who have or are at risk of 
genital HSV during pregnancy. Prevention eﬀ orts have 
included visual inspection for herpetic lesions at delivery, 
selective use of caesarean section, potential use of 
suppressive antiviral therapy in late pregnancy, and 
behavioural primary prevention messages to reduce 
transmission of HSV to a susceptible mother in late 
pregnancy.35 However, available prevention and treatment 
options are imperfect, are often expensive, and typically 
depend on good existing medical infrastructure. 
Prevention eﬀ orts are hampered by the often 
asymptomatic presentation of maternal HSV infection 
and the preponderance of cases caused by incident rather 
than prevalent maternal infection in some settings, as we 
highlight in these estimates. Additionally, caesarean 
section has associated risks in itself, especially in settings 
with poor medical infrastructure. Thus, increasing these 
procedures in resource-poor settings without clearly 
deﬁ ned prevention beneﬁ ts might do more harm than 
good.
For these reasons, an eﬀ ective new vaccine or 
microbicide developed against genital herpes in adults 
could have an important and needed beneﬁ t in preventing 
neonatal herpes. Recent scientiﬁ c advances hold real 
promise for new HSV vaccine development.36 The primary 
targets of such vaccines are prevention of painful genital 
ulcer disease in tens of millions of adults,8 reduction in 
the negative impact on sexual relationships, and reduction 
in the increased HIV risk associated with genital HSV 
infection.37,38 Within the scope of all conditions aﬀ ecting 
neonatal health, the current estimates suggest that HSV is 
not a major contributor, although its impact could be 
considerably under appreciated in some settings. However, 
if a vaccine or microbicide in adults could indirectly 
reduce neonatal transmission, an additional impact on 
neonatal herpes would not only expand the reach of these 
interventions, but could also partly mitigate the diﬃ  culties 
in preventing this condition through existing 
management. Moreover, the high mortality and long-term 
disability in surviving infants due to neonatal herpes 
could actually translate into a considerable number of 
disability-adjusted life-years and costs that could be 
prevented with a vaccine despite low incidence.39,40 These 
global estimates provide a ﬁ rst insight into the potential 
magnitude of this added beneﬁ t. Better primary data on 
neonatal herpes, particularly in low-resource settings, will 
help deﬁ ne more precisely the potential global health 
impact of critically needed new primary prevention 
measures against HSV infection.36,41
Contributors
KJL did the literature review, data extraction, and estimates calculations, 
and drafted the report. LMN oversaw the study, provided advice as 
required, and coordinated requests for demographic data. ASM provided 
statistical input and advised on neonatal herpes natural history 
parameters. MTM provided statistical advice on the sensitivity analysis. 
KMET assisted with data checking. PV advised on the modelling aspect. 
SLG gave advice on the study, its parameterisation and the wider context, 
and helped redraft the report. All authors contributed to the direction of 
the work, provided technical expertise, and commented on the drafts.
Declaration of interests
ASM reports grants from National Institutes of Health during the 
conduct of the study, and personal fees from Immune Design and 
AiCuris outside the submitted work. LMN has been a full-time employee 
of the US Centers for Disease Control and Prevention for the past 
15 years, but during the time she worked on this project she was 
seconded to the World Health Organization. All the other authors 
declare no competing interests.
Acknowledgments
We thank Lauri Markowitz (US Centers for Disease Control and 
Prevention, Atlanta, GA) for providing additional data, Monica Patton 
(US Centers for Disease Control and Prevention, Atlanta, GA) for helpful 
discussion, Anna Wald and Stacy Selke (University of Washington, Seattle, 
WA, USA) for help with parameterisation from the study by Brown and 
colleagues 2003, Nathalie Broutet (World Health Organization, Geneva) for 
commenting on the manuscript drafts, Gretchen Stevens (World Health 
Organization, Geneva) for statistical advice, Jessica Ho and 
Ann-Beth Moller (World Health Organization, Geneva) for advising on 
access to population and births data, and Janet Petitpierre (World Health 
Organization, Geneva) for helping with the ﬁ gures. KJL, KMET, and PV 
thank the National Institute for Health Research (NIHR) Health Protection 
Research Unit (HPRU) in Evaluation of Interventions at the University of 
Bristol for research support. This work was funded by the UNDP/UNFPA/
UNICEF/WHO/World Bank Special Programme of Research, 
Development and Research Training in Human Reproduction. 
WHO commissioned the study, advised as required, coordinated data 
requests, helped with redrafts, and approved manuscript submission. 
KJL had full access to all the data in the study and had ﬁ nal responsibility 
for the decision to submit for publication. SLG is a staﬀ  member of the 
World Health Organization, and LMN was a WHO staﬀ  member during 
her work on this article. KJL received separate funding from the World 
Health Organization, USAID/PATH, Health Protection Scotland, Sexual 
Health 24, and the National Institute for Health Research (NIHR) Health 
Protection Research Unit (HPRU) in Evaluation of Interventions at the 
University of Bristol during the course of this study. ASM received funding 
from the National Institutes of Health (NIH P01-A1-030731-23) during the 
study. PV was additionally supported by the National Institute for Drug 
Abuse [grant number R01 DA037773-01A1] and the Bill and Melinda Gates-
funded HIV Modelling Consortium, and acknowledges further support 
from the NIHR HPRU in STIs and BBV. These funders had no role in the 
writing of the report nor the decision to submit it for publication. The 
authors alone are responsible for the views expressed in this Article and 
they do not necessarily represent the views, decisions, or policies of the 
institutions with which they are aﬃ  liated, the World Health Organization, 
the NHS, the NIHR, the Department of Health, or Public Health England.
References
1 Corey L, Wald A. Maternal and neonatal herpes simplex virus 
infections. N Engl J Med 2009; 361: 1376–85.
2 Kimberlin DW. Herpes simplex virus infections of the newborn. 
Semin Perinatol 2007; 31: 19–25.
3 Ambroggio L, Lorch SA, Mohamad Z, Mossey J, Shah SS. 
Congenital anomalies and resource utilization in neonates infected 
with herpes simplex virus. Sex Transm Dis 2009; 36: 680–85.
Articles
e309 www.thelancet.com/lancetgh   Vol 5   March 2017
4 Handsﬁ eld HH, Waldo AB, Brown ZA, et al. Neonatal herpes 
should be a reportable disease. Sex Transm Dis 2005; 32: 521–25.
5 Flagg EW, Weinstock H. Incidence of neonatal herpes simplex virus 
infections in the United States, 2006. Pediatrics 2011; 127: e1–8.
6 Gantt S, Muller WJ. The immunologic basis for severe neonatal 
herpes disease and potential strategies for therapeutic intervention. 
Clin Dev Immunol 2013; 2013: 369172.
7 Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. Eﬀ ect of 
serologic status and cesarean delivery on transmission rates of 
herpes simplex virus from mother to infant. JAMA 2003; 
289: 203–09.
8 Looker KJ, Magaret A, Turner KME, Vickerman P, Gottlieb SL, 
Newman LM. Global estimates of prevalent and incident herpes 
simplex virus type 2 infections in 2012. PLoS One 2015; 1: e114989.
9 Looker KJ, Magaret A, May MT, et al. Global and regional estimates 
of prevalent and incident herpes simplex virus type 1 infections in 
2012. PLoS One 2015; 10: e0140765.
10 Looker KJ, Garnett GP, Schmid GP. An estimate of the global 
prevalence and incidence of herpes simplex virus type 2 infection. 
Bull World Health Organ 2008; 86: 805–12.
11 Looker KJ, Garnett GP. A systematic review of the epidemiology 
and interaction of herpes simplex virus types 1 and 2. 
Sex Transm Infect 2005; 81: 103–07.
12 Smith JS, Robinson NJ. Age-speciﬁ c prevalence of infection with 
herpes simplex virus types 2 and 1: a global review. J Infect Dis 2002; 
186 (suppl 1): S3–28.
13 Pena KC, Adelson ME, Mordechai E, Blaho JA. Genital herpes 
simplex virus type 1 in women: detection in cervicovaginal 
specimens from gynecological practices in the United States. 
J Clin Microbiol 2010; 48: 150–53.
14 Handel S, Klingler EJ, Washburn K, Blank S, Schillinger JA. 
Population-based surveillance for neonatal herpes in New York City, 
April 2006–September 2010. Sex Transm Dis 2011; 38: 705–11.
15 Kropp RY, Wong T, Cormier L, et al. Neonatal herpes simplex virus 
infections in Canada: results of a 3-year national prospective study. 
Pediatrics 2006; 117: 1955–62.
16 United Nations, Department of Economic and Social Aﬀ airs, 
Population Division, Population Estimates and Projections Section. 
http://esa.un.org/unpd/wpp/unpp/panel_indicators.htm. 
(accessed April 23, 2014).
17 Phipps W, Saracino M, Magaret A, et al. Persistent genital herpes 
simplex virus-2 shedding years following the ﬁ rst clinical episode. 
J Infect Dis 2011; 203: 180–87.
18 Delaney S, Gardella C, Saracino M, Magaret A, Wald A. 
Seroprevalence of herpes simplex virus type 1 and 2 among 
pregnant women, 1989–2010. JAMA 2014; 312: 746–47.
19 Ashley RL, Eagleton M, Pfeiﬀ er N. Ability of a rapid serology test to 
detect seroconversion to herpes simplex virus type 2 glycoprotein G 
soon after infection. J Clin Microbiol 1999; 37: 1632–33.
20 Ashley-Morrow R, Krantz E, Wald A. Time course of seroconversion 
by HerpeSelect ELISA after acquisition of genital herpes simplex 
virus type 1 (HSV-1) or HSV-2. Sex Transm Dis 2003; 30: 310–14.
21 Xu F, Gee JM, Naleway A, et al. Incidence of neonatal herpes 
simplex virus infections in two managed care organizations: 
implications for surveillance. Sex Transm Dis 2008; 35: 592–98.
22 Mark KE, Kim HN, Wald A, Gardella C, Reed SD. Targeted prenatal 
herpes simplex virus testing: can we identify women at risk of 
transmission to the neonate? Am J Obstet Gynecol 2006; 194: 408–14.
23 Morris SR, Bauer HM, Samuel MC, Gallagher D, Bolan G. Neonatal 
herpes morbidity and mortality in California, 1995–2003. 
Sex Transm Dis 2008; 35: 14–18.
24 Mahnert N, Roberts SW, Laibl VR, Sheﬃ  eld JS, Wendel GD, Jr. 
The incidence of neonatal herpes infection. Am J Obstet Gynecol 
2007; 196: e55–56.
25 Hemelaar SJ, Poeran J, Steegers EA, van der Meijden WI. 
Neonatal herpes infections in The Netherlands in the period 
2006–2011. J Matern Fetal Neonatal Med 2015; 28: 905–09.
26 Jones CA, Raynes-Greenow C, Isaacs D, Neonatal HSV Study 
Investigators, Contributors to the Australian Paediatric Surveillance 
Unit. Population-based surveillance of neonatal herpes simplex 
virus infection in Australia, 1997–2011. Clin Infect Dis 2014; 
59: 525–31.
27 Perti T, Nyati M, Gray G, et al. Frequent genital HSV-2 shedding 
among women during labor in Soweto, South Africa. 
Infect Dis Obstet Gynecol 2014: 258291.
28 Schacker T, Zeh J, Hu HL, Hill E, Corey L. Frequency of 
symptomatic and asymptomatic herpes simplex virus type 2 
reactivations among human immunodeﬁ ciency virus-infected men. 
J Infect Dis 1998; 178: 1616–22.
29 Augenbraun M, Feldman J, Chirgwin K, et al. Increased genital 
shedding of herpes simplex virus type 2 in HIV-seropositive 
women. Ann Intern Med 1995; 123: 845–47.
30 The Bill & Melinda Gates Foundation to Fund Disease Surveillance 
Network in Africa and Asia to Prevent Childhood Mortality and 
Help Prepare for the Next Epidemic. http://www.gatesfoundation.
org/Media-Center/Press-Releases/2015/05/Child-Health-and-
Mortality-Prevention-Surveillance-Network (accessed Nov 25, 2015).
31 Langenberg AG, Corey L, Ashley RL, Leong WP, Straus SE. 
A prospective study of new infections with herpes simplex virus 
type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med 
1999; 341: 1432–38.
32 Brown ZA, Selke S, Zeh J, et al. The acquisition of herpes simplex 
virus during pregnancy. N Engl J Med 1997; 337: 509–15.
33 Gardella C, Brown Z, Wald A, et al. Risk factors for herpes simplex 
virus transmission to pregnant women: a couples study. 
Am J Obstet Gynecol 2005; 193: 1891–99.
34 Jamieson DJ, Theiler RN, Rasmussen SA. Emerging infections and 
pregnancy. Emerg infect Dis 2006; 12: 1638–43.
35 Gardella C, Brown Z. Prevention of neonatal herpes. BJOG 2011; 
118: 187–92.
36 Johnston C, Gottlieb SL, Wald A. Status of vaccine research and 
development of vaccines for herpes simplex virus prepared for 
WHO PD-VAC. Vaccine 2016; 34: 2948–52.
37 Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, 
Hayes RJ. Herpes simplex virus 2 infection increases HIV 
acquisition in men and women: systematic review and 
meta-analysis of longitudinal studies. AIDS 2006; 20: 73–83.
38 Masese L, Baeten JM, Richardson BA, et al. Changes in the 
contribution of genital tract infections to HIV acquisition among 
Kenyan high-risk women from 1993 to 2012. AIDS 2015; 
29: 1077–85.
39 Fisman DN, Lipsitch M, Hook EW, Goldie SJ. Projection of the 
future dimensions and costs of the genital herpes simplex type 2 
epidemic in the United State. Sex Transm Dis 2002; 29: 608–22.
40 GBD 2013 DALYs and HALE Collaborators, Murray CJ, Barber RM, 
et al. Global, regional, and national disability-adjusted life years 
(DALYs) for 306 diseases and injuries and healthy life expectancy 
(HALE) for 188 countries, 1990–2013: quantifying the 
epidemiological transition. Lancet 2015; 386: 2145–91.
41 Gottlieb SL, Low N, Newman LM, Bolan G, Kamb M, Broutet N. 
Toward global prevention of sexually transmitted infections (STIs): 
the need for STI vaccines. Vaccine 2014; 32: 1527–35.
